Afatinib dimaleate,850140-73-7
- 品牌:absin
- 型号:abs819524
- 产地:中国
- 供应商:爱必信(上海)生物科技有限公司
- 供应商报价:¥650
- 标签:Afatinib dimaleate,850140-73-7、Afatinib dimaleate,850140-73-7价格、Afatinib dimaleate,850140-73-7厂家、双马来酸盐阿法替尼;阿法替尼二马来酸盐;BIBW2992-MA2、Absin、爱必信(上海)生物科技有限公司
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
YZ剂描述: 产品名称:Afatinib dimaleate 产品别名:双马来酸盐阿法替尼;阿法替尼二马来酸盐 英文别名:BIBW2992-MA2 靶点:EGFR;HER2 CAS:850140-73-7 纯度:>98% 外观:off white powder 保存方法:Store at -20°C 描述: Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. 溶解性:DMSO : 93 mg/mL (129.5 mM) 体外研究: In cell-free in vitro kinase assays, Afatinib (BIBW2992) dimaleate shows potent activity against wild-type and mutant forms of EGFR and HER2, similar to Gefitinib in potency for L858R EGFR, but about 100-fold more active against the Gefitinib-resistant L858R-T790M EGFR double mutant, with an IC50 of 10 nM. BIBW2992 is furthermore comparable to Lapatinib and Canertinib for in vitro potency against HER2, with an IC50 of 14 nM. The most sensitive kinase in this evaluation is lyn with an IC50 of 736 nM[1]. Afatinib is an irreversible inhibitor of these ErbB family receptors. Esophageal squamous cell carcinoma (ESCC) cell lines are sensitive to Afatinib with IC50 concentrations at lower micro-molar range (at 48 hour incubation: HKESC-1=78 nM, HKESC-2=115 nM, KYSE510=3.182 μM, SLMT-1=4.625 μM and EC-1=1.489 μM; and at 72 hour incubation: HKESC-1=2 nM, HKESC-2=2 nM, KYSE510=1.090 μM, SLMT-1=1.161 μM and EC-1=109 nM) with a maximum growth inhibition over 95%. Afatinib can strongly induce G0/G1 cell cycle arrest in HKESC-2 and EC-1 in a dose- and time-dependent manner. 体内研究:Afatinib (15 mg/kg) strongly inhibits the growth of HKESC-2 tumor once the treatment began. Average tumor sizes of vehicle and treatment at end point are 348±24 mm3 and 108±36 mm3 respectively, showing significantly difference between them. And apparently tumor size does not bounce back in a short period of time after the end of Afatinib administration. Without rapid change of body weight throughout the treatment shows that the toxicity of Afatinib is minimal and this drug is well tolerated. 产品信息订购:
产品更多信息请进入爱必信网站咨询 |